Bausch Health Companies Inc Stock Price, News & Analysis

Bausch Health Companies Inc. (NYSE/TSX: BHC) and Salix Pharmaceuticals announced the winners of the 2022 Salix Gastrointestinal Health Scholars Program, awarding $10,000 each to 10 students living with gastrointestinal diseases. This marks the third consecutive year of the program which received over 150 applications. The scholarship aims to assist students in their academic pursuits amid health challenges. The recipients span undergraduate and graduate categories, showcasing the company's commitment to supporting education for those impacted by GI conditions.

Bausch Health Companies Inc. (NYSE/TSX: BHC) announced the results of its 2022 annual meeting of shareholders held on June 21, 2022. All 12 nominated directors were elected, with Thomas J. Appio as CEO expressing gratitude towards former Board member Joseph C. Papa who resigned. John A. Paulson fills the vacancy and will serve as Board Chair. Shareholders approved executive compensation, amendments to the 2014 Omnibus Incentive Plan, and appointed PricewaterhouseCoopers LLP as the independent auditor until the 2023 meeting. Full voting results will be reported on Form 8-K.

Bausch Health Companies Inc. (NYSE/TSX: BHC) has announced its presentation during the Annual Meeting of Shareholders held on June 21, 2022. The presentation highlights the company's diversified pharmaceutical operations, focusing on improving health outcomes through various products in gastroenterology, neurology, and eye health, primarily via its ownership of Bausch + Lomb. The company has also filed a Form 8-K detailing this presentation, available on its Investor Relations page, reinforcing its commitment to advancing global health.

Bausch Health Companies Inc. (NYSE/TSX: BHC) and its gastroenterology business, Salix Pharmaceuticals, will present new data on XIFAXAN® (rifaximin) at the European Association for the Study of the Liver's International Liver Congress™ 2022 in London from June 22-26, 2022. The research focuses on identifying factors precipitating overt hepatic encephalopathy (OHE) and aims to improve management strategies, reducing hospitalization risks. Salix, dedicated to addressing liver disease, emphasizes its role in enhancing patient care through research and development.

Bausch Health Companies (NYSE/TSX: BHC) announced it is suspending the IPO plans for its Solta Medical business due to challenging market conditions. Solta, a leader in medical aesthetics, offers advanced skin rejuvenation and body contouring solutions. The company aims to focus on driving Solta's revenue and operational milestones while retaining it within the Bausch Health portfolio to aid in deleveraging its balance sheet. CEO Thomas J. Appio expressed confidence in Solta's growth and market potential.

Bausch Health Companies Inc. (NYSE/TSX: BHC) announced that it will present seven research posters for its products XIFAXAN®, TRULANCE®, and PLENVU® at Digestive Disease Week 2022 from May 21-24, 2022, in San Diego, California. The posters highlight significant findings, such as the efficacy of XIFAXAN in managing hepatic encephalopathy and IBS-D, TRULANCE's rapid response in treating IBS-C, and PLENVU’s high-quality bowel cleansing for colonoscopy preparations. The research results will be publicly accessible on DDW's ePoster website starting May 21, 2022.

KBRA has published its First-Quarter 2022 U.S. Bank Compendium, offering insights into the banking sector's performance. The report highlights the impact of inflation on vehicle prices and auto loan exposures within the KBRA-rated banks. It includes summaries of 1Q22 results for publicly traded U.S. banks, focusing on key performance metrics and credit ratios. Additionally, the Compendium features the top 10 low-cost deposit franchises and a detailed supplement of 171 debt issues rated by KBRA.

Bausch Health Companies Inc. (NYSE/TSX: BHC) announced its participation in investor conferences, including the Goldman Sachs Leveraged Finance and Credit Conference on May 12, 2022, and the Barclays High Yield Bond & Syndicated Loan Conference on May 24, 2022. Key executives such as Tom Vadaketh and Christina Cheng will represent the company. Live webcasts of these events will be accessible on the Investor Relations page of their website. Bausch Health focuses on enhancing global health through a diverse range of pharmaceutical products.

Bausch + Lomb Corporation and Bausch Health Companies announced the closing of Bausch + Lomb's IPO, selling 35 million shares at $18.00 each, generating $630 million. Bausch Health retains approximately 90% of Bausch + Lomb's shares. The IPO proceeds and new loans will be used to repay existing debts, including Bausch Health’s 6.125% Notes due 2025. Bausch Health also canceled the redemption of its 9.000% Senior Notes due 2025. The IPO began trading under the ticker symbol BLCO on May 6, 2022.